Picoplatin

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Picoplatin
Picoplatin.png
Names
IUPAC name
azane; 2-methylpyridine; platinum(2+); dichloride
Identifiers
3D model (Jmol)
ChemSpider
ECHA InfoCard 100.205.233
UNII
Properties
C6H10Cl2N2Pt
Molar mass 376.14 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
N verify (what is YesYN ?)
Infobox references

Picoplatin is a platinum-based antineoplastic agent in clinical development by Poniard Pharmaceuticals (previously NeoRx) for the treatment of patients with solid tumors.[1]

In Phase I and Phase II clinical trials, picoplatin demonstrated activity in a variety of solid tumors, including lung, ovarian, colorectal and hormone-refractory prostate cancer.[2] However, in Phase III trials, picoplatin failed to hit its primary endpoint for advanced small cell lung cancer.[3] Hopes are now pinned on its use for metastatic colorectal cancer.[4]

References[edit]